In colorectal cancer (CRC), it has been demonstrated that patients with mismatch repair deficiency (dMMR) are good responders to anti‐PD‐1/PD‐L1 immunotherapy, which indicates the mismatch repair (MMR) status can be used as a potential candidate for anti‐PD‐1/PD‐L1 therapy in CRCs 12. This evidence concerns the gene CD274 and mismatch repair cancer syndrome 1.